Study to Assess Tolerability and Safety and Antibody Response to G17DT in Gastric Cancer Patients

Inclusion Criteria: * Patients who had had curative resection for histologically confirmed Stage I, II, or III gastric carcinoma or carcinoma of the oesophagogastric junciton. * Male or female patients over 18 years of age. * Patients with a life expectancy of at least four months. * Karnofsky index for performance status of \>70% * Patients must have given written informed consent. Exclusion Criteria: * Gastric or junctional surgery within three weeks of baseline (week 0) or gastric or junctional surgery anticipated in the study period. * History of other malignant disease within the previous five years, except non-melanomatous skin cancer or in situ carcinoma of the uterine cervix. * Previous use (within the six weeks prior to the screening visit of the study), concomitant use, or anticipated use (up to week 16), of chemotherapy or immunotherapy. * Previous use (within the six weeks prior to the screening visit of the study), concomitant use, or anticipated use (up to week 16), of radiotherapy or any other anti-cancer therapy. * Previous use (within the four weeks prior to the screening visit of the study), concomitant use, or anticipated use (up to week 16), of immunosuppressants, including systemic corticosteroids. * Known immunodeficiency. * Females who were pregnant, planning to become pregnant or lactating. Women, who in the opinion of the investigator were of child bearing potential, were to have a negative pregnancy test before study drug administration. * Patients taking part in another study involving an investigational or licensed drug or device in the three months preceding enrolment or up to week 16 during this study. * Previous G17DT treatment. * Haematological indicators: Haemoglobin \<10.0g/dl Neutrophils \< 2.0 x 109/l Platelets \<100 x 109/l